News – Page 6 – Hamlet Pharma

Merger between Hamlet Pharma AB and SelectImmune Pharma AB. VISIT SELECTIMMUNE WEBSITE

News
- Media Archive
Drug Development
- Alpha1H
  - Bladder Cancer
  - Brain tumor
- BAMLET
  - Colon cancer
  - Oral cancer
Research
- The History of HAMLET
- Publications
About Hamlet Pharma
- About Hamlet Pharma
- Patents
Finance and Investor Relations
Contact Us
Search for:

Press enter to begin your search

Merger between Hamlet Pharma AB and SelectImmune Pharma AB. VISIT SELECTIMMUNE WEBSITE

Feb 03 2020

Love0

Hamlet Pharma tillförs 12,95 miljoner kronor

By Hamlet Pharma Pressmeddelande

Pressmeddelande, Lund 3 februari, 2020 Hamlet Pharma tillförs 12,95 miljoner SEK genom inlösen av teckningsoptioner utfärdade i samband med den riktade emissionen från den 1…

Read More

« Previous 1 … 4 5 6

Reset all ×
2020 ×
2022 ×
2023 ×

61 posts found

Filter by languages

English (21)
Q22022 (1)
Swedish (11)

Filter by years

2023 (21)
2022 (23)
2021 (31)
2020 (17)
2019 (7)
2018 (4)
2017 (5)

Show (61)

Cancel

Reset all ×
2020 ×
2022 ×
2023 ×

Subscribe

To receive email alerts about Hamlet Pharma, you can subscribe to our news via Cision. Click here to go to Hamlet Pharma’s page on Cision, then click the envelope icon under Subscribe.

HAMLET Pharma AB is a pharmaceutical company with strong links to research, working with natural and biological substances.

© 2025 Hamlet Pharma.

News
- Media Archive
Drug Development
- Alpha1H
  - Bladder Cancer
  - Brain tumor
- BAMLET
  - Colon cancer
  - Oral cancer
Research
- The History of HAMLET
- Publications
About Hamlet Pharma
- About Hamlet Pharma
- Patents
Finance and Investor Relations
Contact Us
Search for:

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

HAMLET Pharma, listed on Spotlight, develops new drugs for the treatment and prevention of cancer, based on the discovery of the tumoricidal protein-lipid complex, HAMLET. HAMLET has shown therapeutic efficacy in animal models and effects in clinical proof-of-concept studies. The Alpha1H peptide drug candidate, reproduces the effects of HAMLET and has demonstrated therapeutic efficacy in patients with bladder cancer, where cinical trials are ongoing. Bladder cancer is a common and costly form of cancer, with few successful new treatment options. The company is further exploring the use of Alpha1H for other cancer indications, including brain tumors. In addition, Hamlet Pharma develops BAMLET, which is a HAMLET-like complex formed by bovine α-lactalbumin. Data from animal models show promising effects of local BAMLET treatment against colon cancer.

Contact us

BMC D10

Klinikgatan 32

SE-222 42 Lund Sweden

+4640122500 info@hamletpharma.com

About Hamlet Pharma
Patents

European union

Horizon 2020